NeueHealth — Q1 2025 Earnings Presentation
9 slides from NeueHealth's earnings presentation, May 8, 2025
Slide 1: NeueHealth First Quarter 2025 Earnings Presentation
NeueHealth First Quarter 2025 - Earnings Presentation May 8, 2025 Privileged & Confidential | © 2024
Slide 2: Disclaimer
Disclaimer Statements made in this presentation that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning possible or assumed future re
Slide 3: NeueHealth: A Value-Driven Healthcare Company
NeueHealth: A Value-Driven Healthcare Company Driving Value in Healthcare for All We believe that all health consumers are entitled to high-quality, coordinated healthcare. By uniquely aligning the interests of health consumers, providers, and payors, we are making high-quality healthcare accessible
Slide 4: Overview of Q1 2025 Results
Overview of Q1 2025 Results Strong Results Through Q1 Position NeueHealth to Drive Long-Term, Sustainable Growth in 2025 and Beyond Enterprise Metrics ($M) Revenue Gross Margin Adj. Operating Cost Ratio(1) Adjusted EBITDA(2) Key Considerations • Q1 ‘25 Revenue of $215.8 million, in-line with expecta
Slide 5: Balance Sheet and Liquidity Highlights
Balance Sheet and Liquidity Highlights Summary Balance Sheet Q1’25 Key Considerations March 31, March 31, • $239.4 million in total cash and investments, including $94.3 million in ($ in thousands) 2025 2024 Assets our regulated entities. Cash and Cash Equivalents $138,101 $83,295 • Non-regulated ca
Slide 6: Appendix
Appendix
Slide 7: Non-GAAP Reconciliation: Adjusted EBITDA
Non-GAAP Reconciliation: Adjusted EBITDA Three Months Ended March 31, March 31, ($ in thousands) 2025 2024 Net Loss $ (10,848) $ (4,177) Loss from discontinued operations 9,410 9,865 EBITDA adjustments from continuing operations Interest expense 6,637 2,930 Income tax expense 111 663 Depreciation an
Slide 8: Non-GAAP Reconciliation: Adjusted Operating Cost Ratio
Non-GAAP Reconciliation: Adjusted Operating Cost Ratio Three Months Ended March 31, March 31, ($ in thousands) 2025 2024 GAAP Operating Cost Ratio 22.6% 27.2% Impact of share-based and other long-term incentive (2.6)% (7.6)% compensation expense Impact of held-for-sale operations 0.0% (2.4)% Impact
Slide 9: Slide 9